AG2304

**AG2304** is an oral Ahn-Gook pharmaceutical product in clinical development for primary hypercholesterolemia. A Phase 1 crossover pharmacokinetic study compares AG2304 with coadministration of AG23041 and AG23042, indicating that AG2304 is a fixed-dose combination product containing those two separately administered active components. The publicly available trial records do not disclose the non-code ingredient identities or molecular targets; therefore, a target-level mechanism cannot be assigned reliably. A Phase 3 study in patients with primary hypercholesterolemia has been completed. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06916169))

Other names

AG 2304TAG2304TAG-2304T